Vimentin Antibody (LN-6) - IHC-Prediluted
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-48190
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Mouse, Rat, Porcine, Bovine, Feline, Rabbit, Sheep
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgM Kappa Clone # LN-6
Format
IHC-Prediluted
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Human thymic nuclear extract (Uniprot: P08670)
Localization
Cytoplasmic
Specificity
This monoclonal antibody reacts with a 58kDa protein identified as vimentin. It reacts with a non-hematopoietic epitope of vimentin and shows no cross-reaction with other closely related intermediate filament proteins (IFPs) such as desmin, keratin, neurofilament, and glial fibrillary acid protein. Vimentin is ubiquitously expressed in mesenchymal cells such as fibroblasts, smooth muscle cells, and endothelium. Antibody against vimentin is useful as part of an antibody panel for differential diagnosis of tumors of unknown origin.Ab-2 does not react with leukocyte common antigen-positive tissues such as lymphomas and leukemias.
Marker
Mesenchymal Cell Marker
Clonality
Monoclonal
Host
Mouse
Isotype
IgM Kappa
Theoretical MW
53.6 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Description
The prediluted antibody does not require any mixing, dilution, reconstitution, or titration; the antibody is ready-to-use and optimized for staining.
Scientific Data Images for Vimentin Antibody (LN-6) - IHC-Prediluted
Immunohistochemistry-Paraffin: Vimentin Antibody (LN-6) - IHC-Prediluted [NBP2-48190]
Immunohistochemistry-Paraffin: Vimentin Antibody (LN-6) - IHC-Prediluted [NBP2-48190] - Human Melanoma stained with Vimentin Monoclonal Antibody (LN-6).Applications for Vimentin Antibody (LN-6) - IHC-Prediluted
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Immunohistochemistry (Formalin-fixed): 0.1-0.2ug/ml for 30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes.
Optimal dilution for a specific application should be determined.
Optimal dilution for a specific application should be determined.
Formulation, Preparation, and Storage
Purification
Protein L or PEG purified
Formulation
10 mM PBS with 0.05% BSA
Format
IHC-Prediluted
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: Vimentin
Activated macrophages have been shown to secrete phosphorylated vimentin which can be stimulated by a variety of pathophysiological factors including oxidized low-density lipoproteins and TNF-alpha or inhibited by IL-10 (1). The vimentin protein is often expressed at the cell surface playing a role in cell-cell interactions, tissue damage and repair, immune response, and pathogen recognition (1). Vimentin functions in many cytoskeletal processes including cell migration, which is highlighted by its upregulation during epithelial-to-mesenchymal transition (EMT) (4,5). Vimentin is a commonly used marker for EMT and is expressed by many tumor types (5). For example, high metastasis of oral squamous cell carcinomas also showed high vimentin positive expression in immunohistochemical staining analysis (5). A number of vimentin targeting compounds are in cancer-related clinical trials, however, given the multifunctional role of vimentin, the effect of inhibition on non-malignant cells needs to be thoroughly examined (5).
References
1. Ramos, I., Stamatakis, K., Oeste, C. L., & Perez-Sala, D. (2020). Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21134675
2. Uniprot (P08670)
3. Morrow, C. S., & Moore, D. L. (2020). Vimentin's side gig: Regulating cellular proteostasis in mammalian systems. Cytoskeleton (Hoboken, N.J.). https://doi.org/10.1002/cm.21645
4. van Bodegraven, E. J., & Etienne-Manneville, S. (2020). Intermediate filaments against actomyosin: the david and goliath of cell migration. Current Opinion in Cell Biology. https://doi.org/10.1016/j.ceb.2020.05.006
5. Strouhalova, K., Prechova, M., Gandalovicova, A., Brabek, J., Gregor, M., & Rosel, D. (2020). Vimentin Intermediate Filaments as Potential Target for Cancer Treatment. Cancers. https://doi.org/10.3390/cancers12010184
Alternate Names
VIM
Gene Symbol
VIM
Additional Vimentin Products
Product Documents for Vimentin Antibody (LN-6) - IHC-Prediluted
Product Specific Notices for Vimentin Antibody (LN-6) - IHC-Prediluted
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...